Ligand Pharmaceuticals (LGNYZ) EBT (2016 - 2025)
Historic EBT for Ligand Pharmaceuticals (LGNYZ) over the last 16 years, with Q3 2025 value amounting to $141.1 million.
- Ligand Pharmaceuticals' EBT rose 232648.68% to $141.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $63.0 million, marking a year-over-year increase of 708.15%. This contributed to the annual value of $2.5 million for FY2024, which is 9604.46% down from last year.
- Ligand Pharmaceuticals' EBT amounted to $141.1 million in Q3 2025, which was up 232648.68% from $11.2 million recorded in Q2 2025.
- Ligand Pharmaceuticals' 5-year EBT high stood at $141.1 million for Q3 2025, and its period low was -$65.4 million during Q2 2024.
- In the last 5 years, Ligand Pharmaceuticals' EBT had a median value of $11.2 million in 2025 and averaged $14.6 million.
- In the last 5 years, Ligand Pharmaceuticals' EBT plummeted by 216212.55% in 2024 and then skyrocketed by 232648.68% in 2025.
- Ligand Pharmaceuticals' EBT (Quarter) stood at $17.9 million in 2021, then skyrocketed by 35.0% to $24.1 million in 2022, then decreased by 29.18% to $17.1 million in 2023, then crashed by 329.28% to -$39.2 million in 2024, then skyrocketed by 460.04% to $141.1 million in 2025.
- Its last three reported values are $141.1 million in Q3 2025, $11.2 million for Q2 2025, and -$50.2 million during Q1 2025.